Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer.

CONCLUSION: In patients with mCSPC, ADT plus docetaxel or ADT plus abiraterone/prednisone is recommended. In particular in patients with pre-existing cardiovascular disease, ADT should be considered with a GnRH (gonadotropin-releasing hormone) antagonist to reduce the risk of cardiotoxic side effects. PMID: 31127324 [PubMed - as supplied by publisher]
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Tags: Urologe A Source Type: research

Related Links:

Rahul JenaIndian Journal of Urology 2020 36(4):327-328
Source: Indian Journal of Urology - Category: Urology & Nephrology Authors: Source Type: research
(Lawson Health Research Institute) A new study from Lawson Health Research Institute and Western University illustrates how the gut microbiome interacts with an oral medication in prostate cancer patients, suggesting bacteria in the gut play a role in treatment outcomes. The findings, published in Nature Communications, highlight how the drug abiraterone acetate is metabolized by bacteria in the gut to reduce harmful organisms while promoting those that fight cancer. The team suspects this is one of many examples of how the microbiome influences our response to medications.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
AbstractApalutamide (Erleada®) is an oral selective androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. It is approved in the EU and the USA for the treatment of adult men with metastatic castration-sensitive prostate cancer (mCSPC). In a multinational, phase III study (TITAN) in this patient population, the addition of apalutamide (240  mg once daily) to androgen deprivation therapy (ADT) significantly improved median radiographic progression-free survival (rPFS), median overall survival (OS) and the median time to cytotoxic chemotherapy, while maintaining health-related q...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Abstract It has been earlier reported that partially saturated canthaxanthin (PSC) from Aspergillus carbonarius mutant is non-toxic, has anti-lipid peroxidation activity and can induce apoptosis in prostate cancer cell lines. In the present study, the antiaging effect of PSC was explored in D-galactose administered male wistar rats. 8-10 weeks old, male wistar rats were randomly divided into (i) Vehicle Control Group (VCG), (ii) Aged Control Group (ACG), (iii) Aged + α Lipoic Acid Group (ALG) and (iv) Aged + Partially saturated canthaxanthin Group (APG). Rats received D-galactose ...
Source: Biogerontology - Category: Geriatrics Authors: Tags: Biogerontology Source Type: research
DB Nandini, Roopa S Rao, BS Deepak, Praveen B ReddyJournal of Oral and Maxillofacial Pathology 2020 24(2):405-405 Isothicyanates present in cruciferous vegetables are known to exhibit chemoprevention by various mechanisms. Presently, there is growing evidence that a phytochemical compound known as sulforaphane in these green leafy vegetables is found to be effective in preventing and treating various cancers such as prostate cancer, breast cancer, colon cancer, skin, urinary bladder and oral cancers. This component is naturally present in the broccoli sprouts, kale, cabbage, cauliflower and garden cress and is available a...
Source: Journal of Oral and Maxillofacial Pathology - Category: ENT & OMF Authors: Source Type: research
Susan Feyerabend Residual androgen production causes tumor progression in metastatic, castration-resistant prostate cancer (mCRPC) patients. Abiraterone acetate (AA), a prodrug of abiraterone, is an oral CYP-17 inhibitor that blocks androgen production. It was hypothesized that adherence-enhancing measures (AEM) might be beneficial for mCRPC patients receiving abiraterone acetate plus prednisone (AA + P). This multicenter, prospective, 2-arm trial allocated mCRPC patients who were progressive after docetaxel-based chemotherapy or asymptomatic/mildly symptomatic after failure of an androgen deprivation therapy to Arm ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
We report a case of an extensive and relapsing mandibular osteonecrosis in a male patient, 78 years old, who was referred with painful symptoms associated with extense ulcer in alveolar ridge. The patient had previous history of osteonecrosis after dental extractions, which had already been treated by bone debridement. The oral exam showed an extensive area of necrotic mandibular bone and ulcered oral mucosa.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: 20190729 Source Type: research
A 57-year-old leucoderm patient sought care because of intense pain in the jaw as well as exposed bone in the oral cavity. These signs and symptoms began after the extraction of the dental element 45. During the anamnesis, the patient reported a previous diagnosis of prostate cancer associated with bone metastasis and the use of zoledronic acid for a period of 3 months. Oral and physical examination revealed facial symmetry and direct submandibular lymphadenopathy, and intraoral examination revealed a necrotic bone area in the posterior region of the right mandible associated with purulent exudate.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: 20190513 Source Type: research
Basal cell carcinoma (BCC) is a malignant tumor related to chronic exposure to ultraviolet or ionizing radiation, affecting basal layer skin cells. It affects mainly white people, above 40 years old, in the head and neck region. Therapies include surgical excision, Mohs surgery, and ablation laser therapy. An 85-year-old white male patient, a former smoker and chronic alcoholic, was diagnosed with BCC in vermilion of the lower lip (2017) and in follow-up after surgical excision. He developed prostate cancer (1998) and left parotid gland (2012), treated surgically.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: 20190902 Source Type: research
More News: Alternative and Complementary Therapies | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | Clinical Trials | Docetaxel | Heart | Hormones | Oral Cancer | Prednisone | Prostate Cancer | Study | Taxotere | Urology & Nephrology